LILRB4 and neoplasm: After 40 days of tumor injection, 3 out of 6 mice (50%) died in isotype and only BTZ treated groups, 1 mouse (16.67%) died in anti-LILRB4-treated group, and no mice died in the combination therapy group (anti-LILRB4 + BTZ).